GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates

Company Performance - GeneDx Holdings Corp. reported quarterly earnings of $0.70 per share, significantly exceeding the Zacks Consensus Estimate of $0.20 per share, and compared to a loss of $0.59 per share a year ago, representing an earnings surprise of 250% [1] - The company posted revenues of $95.64 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.96%, and showing an increase from year-ago revenues of $57.42 million [2] - Over the last four quarters, GeneDx Holdings has consistently surpassed consensus EPS estimates [2] Market Performance - GeneDx Holdings shares have underperformed the market, losing about 0.7% since the beginning of the year, while the S&P 500 has gained 4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $74.8 million, and for the current fiscal year, it is $0.52 on revenues of $330.3 million [7] Industry Outlook - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the bottom 48% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of GeneDx Holdings may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]